Stay updated with breaking news from Rexulti. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Rexulti is covered by Medicare and now FDA approved to treat agitation. But, advocates want Medicare coverage for other drugs shown to slow cognitive decline in Alzheimer’s.
Rexulti is the first and only pharmacological treatment approved in the U.S. for agitation associated with dementia due to Alzheimer's disease Valby, Denmark, May 11, 2023 - H. Lundbeck A/S and... | May 11, 2023
Rexulti, a drug for schizophrenia and depression, now has an additional approval for treating agitation in Alzheimer’s disease patients. The FDA decision makes the Otsuka Pharmaceutical and Lundbeck product the first drug approved for this indication.
FDA approved the first drug to treat agitation associated with Alzheimer's disease: Rexulti, a brexpiprazole oral tablet
(PLX AI) - Lundbeck shares are likely to gain today after the company reported positive results in Alzheimer's agitation with its drug Rexulti in a phase 3 trial, analysts said. • Results for treatment